<DOC>
	<DOC>NCT02405260</DOC>
	<brief_summary>This trial is a multi-center, adaptive, randomized, double-blind, placebo- and active- controlled, parallel group, Phase 2 study in subjects with T2DM to evaluate the effect of TTP399 on HbA1c following administration for 6 months.</brief_summary>
	<brief_title>Add Glucokinase Activator to Target A1c</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>A historical diagnosis of Type 2 Diabetes in accordance with the American Diabetes Association (ADA) guidelines, with diagnosis at least 6 months prior to Screening. On a stable (for the last 3 months prior to screening) regimen of metformin monotherapy equivalent of at least 1000 mg once daily. Males, females of childbearing potential (must have a negative pregnancy test and be willing to comply with protocol contraception), and females of nonchildbearing potential. Age 18 to 75 years, inclusive, at the time of screening. HbA1c ≥7.0% and ≤9.5%. Generally stable health without active infection or history of major surgery or significant injuries within the last year. Diagnosis of Type 1 diabetes mellitus, maturityonset diabetes of the young, insulinrequiring Type 2 Diabetes, other unusual or rare forms of diabetes mellitus, or history of diabetic ketoacidosis. Clinically significant abnormal lab values including eGFR &lt;50ml/min/1.73m2, ALT, bilirubin or AST &gt;1.5 X ULN, hypokalemia or other clinically significant electrolyte abnormality. History of myocardial infarction, unstable angina, coronary revascularization, stroke, or transient ischemic attack within 2 years of screening. Presence of symptomatic congestive heart failure. History of cardiac arrhythmias requiring treatment or prophylaxis with drugs or devices during the last 2 years or any history of atrial fibrillation or flutter beyond a single shortterm episode (e.g., lasting 12 days). History or presence of a 2nd degree or greater atrioventricular block in the absence of a pacemaker. A 12lead ECG, from screening or baseline demonstrating QTcF interval &gt;450 msec for males or &gt;47 msec for females. A family or personal history of long QT syndrome. History of pancreatitis. Persistent, uncontrolled hypertension. Presence of chronic active hepatitis (hepatitis B, hepatitis C, nonalcoholic steatohepatitis [NASH]) and/or known liver cirrhosis. Participation in any formal weight loss program, or fluctuation of &gt; 5% in body weight, or having received medications approved for weight loss within 3 months prior to screening. A positive prestudy drug screen. Participation in a clinical trial and receipt of an investigational product within 30 days. Have a history of drug abuse within 2 years of screening or a positive prescreen drug screen. Have a history of hypoglycemic episode requiring glucose, glucagon, or orange juice administered by someone other than the patient within 6 months prior to screening. A history of excessive alcohol consumption within the last 2 years prior to screening Mental or legal incapacitation. Blood donation of approximately 1 pint (500 mL) within 8 weeks. History of MEN2 or family history of medullary thyroid cancer. History of cancer, other than nonmelanoma skin cancer, that required therapy in the 5 years prior study start.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>